Unichem Laboratories Limited, a prominent pharmaceutical company, has announced the completion of a significant financial settlement with the European Commission. The company has paid a fine of €16,753,873.41, including interest, related to the Perindopril drug matter.

Settlement Details

Background and Compliance

The payment follows a series of communications from Unichem Laboratories to its stakeholders. The company had previously informed about this matter through letters dated June 27, 2024, and September 18, 2025. This recent payment marks the conclusion of the issue that has been ongoing for over a year.

Regulatory Compliance

In adherence to regulatory requirements, Unichem Laboratories has duly notified the stock exchanges about the completion of this payment. This notification aligns with the company's obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company's Statement

Pradeep Bhandari, Head – Legal & Company Secretary of Unichem Laboratories, confirmed the payment in an official communication to the stock exchanges. The statement reads, "Today, the company has made payment of fine (including interest) of Euro 16,753,873.41 to European Commission, Brussels, Belgium in the Perindopril drug matter."

This development represents a significant financial event for Unichem Laboratories and marks the resolution of a major regulatory issue with European authorities. The impact of this substantial fine on the company's financials and its implications for future operations in the European market remain to be seen.

Investors and stakeholders of Unichem Laboratories will likely be monitoring how this settlement affects the company's financial position and its strategies moving forward, particularly in the European pharmaceutical market.

Unichem Laboratories , a prominent pharmaceutical company, has received a substantial demand notice from the European Commission related to a long-standing Perindopril case. The notice, amounting to €19.49 million, stems from allegations of breaching EU competition law in a 2005 patent dispute settlement with the Servier Group.

Demand Notice Details

The European Commission's demand breaks down as follows:

Unichem has already made a partial payment through its wholly-owned subsidiary, remitting €2,791,262.76 in installments. This leaves a balance of €16,695,746.29 still payable to the European Commission.

Financial Impact and Company Response

The demand notice presents significant financial implications for Unichem Laboratories:

1. The company had previously made provisions for the principal amount of €13,968,773.00 in its books of account.
2. The interest component of €5,518,236.05 will need to be provided for in the company's financial statements.

Unichem Laboratories is currently evaluating its legal options in consultation with its law firm. The company's management is expected to act based on the advice received, indicating a potential challenge to the demand or exploration of settlement options.

Background of the Case

The demand notice is related to allegations that Unichem and its wholly-owned subsidiary, Niche Generics Ltd, violated EU competition law. The case revolves around a settlement agreement reached in 2005 with the Servier Group concerning a Perindopril patent dispute.

Regulatory Compliance

In compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Unichem Laboratories has duly informed the National Stock Exchange of India Limited and BSE Limited about this development. The company's transparency in disclosing this information underscores its commitment to regulatory compliance and shareholder communication.

As this situation unfolds, stakeholders and industry observers will be keenly watching Unichem Laboratories' next steps in addressing this significant financial demand from the European Commission.